Nathan Sepeda
Director of Data & Analytics
Data updated
Research Footprint
Nathan Sepeda appears in 18 tracked papers (2020–2026), most studied alongside Psilocybin, 5-MeO-DMT and Ibogaine, across Depressive Disorders, Anxiety Disorders and Healthy Volunteers.
Most-cited paper: Effects of Psilocybin-Assisted Therapy on Major Depressive Disorder (1236 citations).
Frequent co-authors: Alan Davis, Frederick Barrett and Roland Griffiths.
Publication Landscape
How the 18 papers Blossom tracks for Nathan Sepeda line up by year, topic, and journal. These are the psychedelic-relevant papers in Blossom's records as of July 2026, not a complete bibliography.
How has Nathan Sepeda's publishing grown?
SourcedTracked papers by publication year. Click a year for the running total.
Don't read as total output: only the 18 of 18 tracked papers with a recorded publication date are counted, and these are the psychedelic-relevant papers Blossom tracks, not a complete bibliography. The current year is still filling in.
What does Nathan Sepeda publish on?
SourcedTracked papers per topic. Orange marks the largest research focus.
Don't read shares as adding to 100%: a paper tagged with several topics counts once per topic. These are the psychedelic-relevant papers Blossom tracks, not a complete bibliography.
Where does Nathan Sepeda publish?
SourcedTracked papers per journal. Orange marks the most-used journal.
Counts the journal recorded on each tracked paper; preprints and papers with no journal on file are not shown. These are the psychedelic-relevant papers Blossom tracks, not a complete bibliography.
Background & Research
Nathan D. Sepeda is a clinical researcher specialising in clinical trials and outcome measurement within psychedelic medicine. He has been a frequent collaborator on multi‑centre and single‑site investigations into the psychological and neurofunctional effects of classic and atypical hallucinogens, contributing to work on psilocybin‑assisted therapy for major depressive disorder, healthy‑volunteer pharmacology studies, and longer‑term follow‑up safety and efficacy assessments. Sepeda's work spans experimental double‑blind comparisons, prospective 12‑month outcome monitoring, and targeted studies of spiritual and religious experience in diverse populations.
His research emphasis is on quantifying experience‑dependent and enduring psychological changes after psychedelic administration and identifying predictors of treatment response. Sepeda has co‑authored pivotal publications from programmes affiliated with major psychedelic research centres and applies interdisciplinary methods — clinical trial design, standardised psychological measures and neurobehavioural assessments — to clarify therapeutic potential, adverse effects and mechanisms of change in psychedelic‑assisted interventions.
Key Impact
Notable for his contributions to clinical and experimental studies of psilocybin-assisted interventions, including trials of major depressive disorder and investigations of enduring psychological and neurofunctional effects.
Collaboration Network
31 collaborators· click a node to visit their profile
Full network →Collaboration Network
See Nathan Sepeda's full collaboration network, shared papers, and research connections.
Compounds
Topics
Top Collaborators
Top Collaborators
Unlock clinical summaries, full texts, and related trial mapping.
Affiliations
Institutions, companies, and organisations Nathan Sepeda is associated with.
Johns Hopkins Center for Psychedelic and Consciousness Research
The Johns Hopkins Center for Psychedelic and Consciousness Research sits within the School of Medicine in Baltimore and is one of the most established programmes of its kind. It opened in 2019 with roughly 17 million dollars in private donations, and was founded under Roland Griffiths, whose earlier psilocybin work helped revive modern clinical study of these compounds. Frederick Barrett took over as director in 2023. The centre studies how classic psychedelics such as psilocybin affect brain function, cognition and mood, and runs trials in conditions including depression, tobacco dependence and anorexia. Its scientists combine clinical trials with neuroimaging and questionnaire measures of the psychedelic experience, and much of the field's shared vocabulary traces back to work done here.
View stakeholder →Johns Hopkins University
academicThe Centre for Psychedelic and Consciousness Research focuses on how psychedelics affect behavior, cognition, brain function, and biological health markers. They have been at the forefront of demonstrating the safety and efficacy of psychedelics for mental disorders, expanding their focus into psilocybin research across multiple mental health conditions, including smoking cessation, major depressive disorder, and cancer-related anxiety.
View stakeholder →